mCRPC

19 registered clinical trials studyying mCRPC — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castra NCT07389187	Shanghai Changzheng Hospital	EARLY_Phase 1
Recruiting	A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001) NCT07103018	K36 Therapeutics, Inc.	Phase 1
Not Yet Recruiting	Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer NCT07104643	TYK Medicines, Inc	Phase 1 / Phase 2
Recruiting	Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer： NCT07093866	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Phase 2
Active Not Recruiting	Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody NCT06866548	Shanghai Changzheng Hospital	EARLY_Phase 1
Recruiting	The Radium-select Study NCT06659926	The Netherlands Cancer Institute	N/A
Recruiting	A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate Cancer NCT07096128	Jinming Zhang	Phase 1
Completed	Study of INKmune in Patients With mCRPC (CaRe Prostate) NCT06056791	Inmune Bio, Inc.	Phase 1 / Phase 2
Active Not Recruiting	Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cance NCT05383079	Peter MacCallum Cancer Centre, Australia	Phase 1 / Phase 2
Recruiting	Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection NCT05413850	Blue Earth Therapeutics Ltd	Phase 1 / Phase 2
Active Not Recruiting	Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer NCT05340374	Peter MacCallum Cancer Centre, Australia	Phase 1 / Phase 2
Unknown	Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment NCT04822961	Impact Therapeutics, Inc.	Phase 2
Active Not Recruiting	A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-N NCT05547061	Cellbion Co., Ltd.	Phase 1 / Phase 2
Completed	Performance of 177Lu-PSMA-I&T for RLT in mCRPC - Prospective Multicenter Swiss Registry Study NCT06830408	University Hospital, Basel, Switzerland	—
Enrolling By Invitation	Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Pr NCT04145375	Zenith Epigenetics	Phase 1 / Phase 2
Recruiting	A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Res NCT03851640	Hinova Pharmaceuticals Inc.	Phase 3
Active Not Recruiting	Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC NCT03395197	Pfizer	Phase 3
Active Not Recruiting	A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Inj NCT02266745	Promontory Therapeutics Inc.	Phase 2
Completed	Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer NCT01818986	University of Texas Southwestern Medical Center	Phase 2